test_CN
主页
问候语
委员会
工业咨询委员会 (IAB)
时间表
初步科学方案
卫星会议
摘要提交
海报展示指南
Poster Abstracts List
Best Abstract Awards Winners
Diabetes
Diabetes Complications
Cardiovascular Disease in Diabetes
Cytokins
Genetics in Diabetes
Diet and Exercise
Diabetes Therapy
Disease Management
Metabolic Syndrome (MS)
MS/ Diabetes in Childhood
Obesity/ Lipids
Guided Poster Tours
注册
Accompanying Persons Program
邀请函
住宿
Kerry Hotel Pudong, Shanghai
Jin Jiang Oriental Hotel
Radisson Blu Hotel Pudong Century Park
赞助和展览
赞助商
一般信息
Before you travel...
入境签证
交通
帮助和提示
意大利代理人
CME
之前的会议
网络广播
CODHy 2011 Webcasting
CODHy 2008 Webcasting
合作伙伴
联系我们
关于上海
第一届亚太地区关于
糖尿病、肥胖和高血压争议到共识会议 (CODHy)
中国上海,2011 年 6 月2 日~ 6 月5 日
 
  Saturday June 4, 2011 Print

 

HALL A

08:30-10:00
Session 14
PREVENTION OF DIABETES
8:30-8:35  Chairpersons: B. Itzhak, Israel & A. El-Sayed, Egypt
 
8:35-8:55  Score for high risk in Diabetes in Asia G. Ning, China
   
8:55-9:15  High prevalence in the Gulf region A. El-Sayed, Egypt
 
9:15-9:35  Difference in candidate gene for T2D in Asia Y.S. Cho, Korea
 
9:35-10:00  Discussion 

10:00-10:30

Coffee Break

10:30-12:00
Session 15
WHAT IS OF SPECIAL IMPORTANCE FOR HYPERTENSION AND ITS TREATMENT IN ASIA?
 
10:30-10:35  Chairpersons: P.M. Nilsson, Sweden & J. Wang, China
 
10:35-10:50  The epidemiological perspectives for populations in transition P.M. Nilsson, Sweden 
 
10:50-11:05  Stroke more important than CHD in Asian countries: Still true? K. Kario, Japan

11:05-11:20  A review of interventions studies including Asian patients with hypertension X. Du, China

11:20-11:35  Which antihypertensive drugs to prefer in Asian patients? J. Wang, China
 
11:35-12:00  Discussion

12:00-12:10

Technical Break

12:10-13:00
Session 16
MEET THE PROFESSOR

12:10-12:15  Chairperson: A. Rubinstein, Israel
 
12:15-12:30  Beta cell function and diabetes in China W. Yang, China
 
Oral Presentations
12:30-12:45  High serum IgA concentrations and risks of impaired fasting glucose, hypertension, and hypercholesterol among children
C.C. Liao, Taiwan, F.C. Sung, T.C. Su, K.L. Chien, Y.T. Lee
 
12:45-13:00  Diabetes complications and BMI in Asia, Africa, Europe, and Latin America: A1chieve baseline data
W. Yang, China, G. Gonzalez-Galvez, P. Home, I.M. Hajjaji, P.N. Chakkarwar, P. Soewondo

13:00-14:00

Lunch Break

14:00-15:30
Session 17

FDA CARDIOVASCULAR ASSESSMENT REQUIREMENTS: IMPLICATIONS FOR CLINICAL RESEARCH IN CHINA

14:00-14:05  Chairpersons: B. Hirshberg, USA & J. Zhao, USA
 
14:05-14:20  Impact of the US FDA cardiovascular assessment requirements on the development of novel antidiabetes drugs B. Hirshberg, USA
 
14:20-14:40  The China KOL's perspective L. Ji, China
 
14:40-15:00  Global CV outcome studies, view point of the Chinese regulatory authority Z. Yang, China
   
15:00-15:30  Discussion

15:30-16:00

Coffee Break

16:00-17:30
Session 18
INDIVIDUALISED THERAPY IN ASIAN T2D PATIENTS
16:00-16:05  Chairperson: M. Hanefeld, Germany
 
Are all Asian patients the same when it comes to diabetes?
Case reports:
16:05-16:25  Germany vs. Japan M. Hanefeld, Germany
16:25-16:45  India A. Kumar, India
16:45-17:05  Cambodia L. Keuky, Cambodia
  
17:05-17:30  Discussion

HALL B

08:30-10:00
Session 19
EXTRA GLYCAEMIC EFFECTS OF INCRETIN BASED THERAPY IN T2D
8:30-8:35  Chairperson: S. Del Prato, Italy
 
8:35-8:55  The heart S. Del Prato, Italy

8:55-9:15  The brain J. Davidson, USA 

9:15-9:35  The vascular system O. Mosenzon Israel
 
9:35-10:00  Discussion 

10:00-10:30

Coffee Break

10:30-12:00
Session 20
TREATMENT GOALS IN DIABETES
10:30-10:35  Chairpersons: E. Standl, Germany & K. Abdul Kadir, Malaysia
 
Should we aim to normalise A1c?
10:35-10:50  Pro: E. Standl, Germany
10:50-11:05  Con: K. Abdul Kadir, Malaysia
 
Drug therapy for Prediabetes:
11:05-11:35  Yes: K.H. Yoon, Korea
  
11:35-12:00  Discussion 

12:00-12:10

Technical Break

12:10-13:00
Session 21
ORAL PRESENTATIONS
12:10-12:20  Chairperson: I. Raz, Israel
 
12:20-12:30  Validity of dietary glycemic load as a predictor of postprandial glycemia and insulinemia in lean, young healthy adults
J. Bao, Australia, F. Atkinson, P. Petocz, W. Willett, J. Brand-Miller
 
12:30-12:40    Cut-off value of 50-gram glucose challenge test for the diagnosis of gestitational Diabetes Mellitus
D. Boriboonhirunsarn, Thailand, T. Lertbunnaphong, P. Khanmali
 
12:40-12:50   The ratio of leg-length over standing height as a predictor of childhood obesity: Results from a longitudinal cohort study
J. Liu, Canada, N. Akseer, B. Faught, J. Hay, J. Cairney 
 
12:50-13:00  The outcome of Beta cell function after early insulin therapy in teh recently diagnosed Type 2 Diabetes (in Egyptian population) our experience in El-Minia University Hospital
Y.M. Mosa, A.M. Mohamed, S.H. El Hini, M.S. Kamel, Egypt, A.S. Salama, G.M. El Sagheer, A.M. Osman

13:00-14:00

Lunch Break

14:00-15:30
Session 22
EVIDENCE FROM CLINICAL TRIALS IN DIABETES

14:00-14:05  Chairperson: L. Van Gaal, Belgium
 
14:05-14:25  Specific OHG effects on CVD I. Raz, Israel
 
14:25-14:45  HDL: Unmet challenge L. Van Gaal, Belgium
 
14:45-15:05  Statin or combination O. Mosenzon, Israel
  
15:05-15:30  Discussion

15:30-16:00

Coffee Break

16:00-17:30
Session 23

NEW TRENDS IN T1D


16:00-16:05  Chairperson: P. Pozzilli, Italy
 
16:05-16:25  The increased incidence of Type 1 Diabetes (T1D) worldwide: What to blame? P. Pozzilli, Italy

16:25-16:45  Promising treatment to limit beta cell destruction J. Palmer, USA

16:45-17:05  Application of technology to the disease management R. Weiss, Israel
 
17:05-17:30  Discussion

HALL C

08:30-10:00
Session 24
HYPERTENSION
8:30-8:35  Chairpersons: P.M. Nilsson, Sweden & J. Wang, China
 
The "Pearls and Perils" of managing hypertension in people with diabetes
8:35-8:50  Pearls: J. Wang, China
8:50-9:05  Perils: X. Du, China

9:05-9:25  ACEs or ARBs as first line treatment of hypertension in diabetes E. Imai, Japan

9:25-9:40  Are all RAAS blockers equal? P.M. Nilsson, Sweden
  
9:40-10:00  Discussion

10:00-10:30

Coffee Break

10:30-12:00
Session 25
SGLT2 INHIBITORS
10:30-10:35: Chairperson: G. Schernthaner, Austria
 
10:35-11:00  The kidney and its role in glucose homeostasis J. Davidson, USA
 
11:00-11:25  Glucosuria as a novel approach in diabetes management G. Schernthaner, Austria
 
11:25-11:40  Clinical development of anti-diabetic agents in China X.H. Guo, China
 
11:40-11:55  Discussion
 
11:55-12:00  Closing Remarks G. Schernthaner, Austria

12:00-12:10

Technical Break

12:10-13:00
Session 26
ORAL PRESENTATIONS
12:10-12:20  Chairperson: V. Hainer, Czech Republic
 
12:20-12:30  Cardiovascular safety of liraglitude: A pooled analysis from Phase II and III liraglutide clinical development studies
Y.Y. Huang, Taiwan, S.P. Marso, A.C. Moses, M.J. Zychma, J.B. Buse
 
12:30-12:40  Association of Paraoxonase 1 Gene polymorphism with Intima media thickness (IMT) of the Carotif arterise in Japaneses Type 2 Diabetic patients
I. Yamamoto, Japan, T. Honda, K. Takada, M. Maeda, S. Nonen, T. Motomura, K. Maeda, Y. Fujio, J. Azuma
 
12:40-12:50  Association of maternal CMI with adverse pregnancy outcomes- difference between South Asian, South East Asian and Australian women
N. Moin, Australia, S. Hendon, J. Bradford, P. Henriksson, M. McLean
 
12:50-13:00  Diabetes Mellitus following liver transplantation: Incidence, glucose monitoring and treatment options in single centre
I. Daskalova, Bulgaria, I. Takarov, E. Odisseeva, T. Lukanova, R. Velichkova, N. Vladov

13:00-14:00

Lunch Break

14:00-15:30
Session 27
CV RISK AND INSULIN RESISTANCE IN CHILDHOOD: THE ASIAN PERSPECTIVE
14:00-14:05  Chairpersons: R. Weiss, Israel & W. Lee, Singapore
 
14:05-14:20  Melanocortin 3 receptor and Melanocortin 4 receptor genetic mutations: The Asian perspective Y.S. Lee, Singapore
 
14:20-14:35  Metabolic syndrome – Early life exposure W. Lee, Singapore
 
14:35-14:50  Obesity and metabolic syndrome in Chinese children H. Wang, China
 
14:50-15:05  Bariatric surgery for obese adolescents with related comorbidity R. Weiss, Israel
 
15:05-15:30  Discussion

15:30-16:00

Coffee Break

16:00-17:30
Session 28
BARIATRIC SURGERY IN OBESITY AND DIABETES IN ASIA
16:00-16:05  Chairperson: G. Schernthaner, Austria
 
Last resort in obese patients
16:05-16:20  Pro: C.K. Huang, Taiwan
16:20-16:35  Con: V. Hainer, Czech Republic
 
Early in the obese patient with risk factors
16:35-16:50  Pro: S.K.H. Wong, China (HK)
16:50-17:05  Con: W.H-H. Sheu, Taiwan
 
17:05-17:30  Discussion

 


主页    联系我们   
 
Copyright © 2007 comtecmed.com. All rights reserved.   The website was last updated on 12/12/2011 Created by     WebStudio.co.il